Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications

BMC Immunology

Volumn 13, Issue , 2012, Pages

  Jimenez Perez, Miriam I ^a,b   Jave Suarez, Luis F ^b   Ortiz Lazareno, Pablo C ^b   Bravo Cuellar, Alejandro ^a,b   Gonzalez Ramella, Oscar ^a   Aguilar Lemarroy, Adriana ^b   Hernandez Flores, Georgina ^b   Pereira Suarez, Ana L ^a   Daneri Navarro, Adrian ^a   del Toro Arreola, Susana ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cervical cancer; MICA; MICB; NK cells; NKG2D; ULBP

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; CARRIER PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; LIGAND; MEMBRANE PROTEIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; RAET1E PROTEIN, HUMAN; SIGNAL PEPTIDE; ULBP1 PROTEIN, HUMAN; ULBP2 PROTEIN, HUMAN; ULBP3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CONTACT; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; UTERINE CERVIX CANCER; CARCINOMA; CELL COMMUNICATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; UTERINE CERVIX TUMOR;

CARCINOMA; CARRIER PROTEINS; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE PROTEINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; UTERINE CERVICAL NEOPLASMS;

EID: 84856622788     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-13-7     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta 1996, 1288(2):F55-F78.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006, 110(5):525-541.
5. Waggoner SE. Cervical cancer. Lancet 2003, 361(9376):2217-2225. 10.1016/S0140-6736(03)13778-6, 12842378.
6. Woodworth CD. HPV innate immunity. Front Biosci 2002, 7:d2058-d2071. 10.2741/woodworth, 12165480.
7. Li C, Houser BL, Nicotra ML, Strominger JL. HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci USA 2009, 106(14):5767-5772. 10.1073/pnas.0901173106, 2667005, 19304799.
8. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998, 161(11):5821-5824.
9. Babu S, Blauvelt CP, Nutman TB. Filarial parasites induce NK cell activation, type 1 and type 2 cytokine secretion, and subsequent apoptotic cell death. J Immunol 2007, 179(4):2445-2456.
10. Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005, 174(7):3992-3998.
11. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27(45):5932-5943. 10.1038/onc.2008.267, 18836474.
12. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331(6013):44-49. 10.1126/science.1198687, 3089969, 21212348.
13. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14(2):123-133. 10.1016/S1074-7613(01)00095-4, 11239445.
14. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7(9):737-744. 10.1038/nri2144, 17673918.
15. Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999, 60(4):323-330. 10.1016/S0198-8859(98)00128-1, 10363723.
16. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 2001, 31(5):1428-1437. 10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4, 11465099.
17. Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, Vinocur JM, Buckanovich RJ, Thompson CB, Levine B, et al. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther 2003, 2(4):446-451.
18. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 2004, 173(2):1078-1084.
19. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008, 8:16. 10.1186/1471-2407-8-16, 2270854, 18208618.
20. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et al. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clin Cancer Res 2009, 15(16):5208-5215. 10.1158/1078-0432.CCR-09-0886, 19671853.
21. Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006, 239(1):22-30. 10.1016/j.cellimm.2006.03.002, 16630603.
22. Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 2011, 6(2):e16899. 10.1371/journal.pone.0016899, 3045385, 21364924.
23. Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010, 70(2):481-489. 10.1158/0008-5472.CAN-09-1688, 2817492, 20068167.
24. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008, 180(11):7249-7258.
25. Hedlund M, Stenqvist A-C, Nagaeva O, Kjellberg L, Wulff M, Baranov V, Mincheva-Nilsson L. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009, 183(1):340-351. 10.4049/jimmunol.0803477, 19542445.
26. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immun 2009, 58(5):641-652.
27. von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf I, Brossart P, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immun 2010, 59(6):829-839.
28. Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res 2007, 13(24):7459-7468. 10.1158/1078-0432.CCR-07-1166, 18094430.
29. Wu JD, Atteridge CL, Wang X, Seya T, Plymate SR. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009, 15(2):632-640. 10.1158/1078-0432.CCR-08-1305, 2775521, 19147769.
30. Ebert EC, Groh V. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology 2008, 124(1):33-41. 10.1111/j.1365-2567.2007.02656.x, 2434382, 18284469.
31. Allegra S, Deleine C, Michael-Jubely R, Gryson C, Boirie Y, Kantakamalakul W, Vasson MP. Implementation of the EGFP-K562 flow cytometric NK test: determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry Part A: The journal of the International Society for Analytical Cytology 2006, 69(9):992-998.
32. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007, 67(18):8444-8449. 10.1158/0008-5472.CAN-06-4230, 17875681.
33. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002, 62(21):6178-6186.
34. Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A, Cid-Arregui A, Jimenez-Perez M, Haramati J, Barros-Nunez P, Gonzalez-Ramella O, Del Toro-Arreola A, Ortiz-Lazareno P, et al. MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int 2011, 11:15. 10.1186/1475-2867-11-15, 3120738, 21631944.
35. van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol 2000, 85(6):681-685. 10.1017/S0958067000020972, 11187963.
36. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002, 188:9-21. 10.1034/j.1600-065X.2002.18802.x, 12445277.
37. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994, 180(2):537-543. 10.1084/jem.180.2.537, 2191610, 8046332.
38. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004, 104(1):170-177. 10.1182/blood-2003-12-4438, 15016654.
39. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaelsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010, 115(6):1166-1174. 10.1182/blood-2009-09-245746, 19903900.
40. Yokoyama WM. The search for the missing 'missing-self' receptor on natural killer cells. Scand J Immunol 2002, 55(3):233-237. 10.1046/j.1365-3083.2002.01054.x, 11940229.
41. Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 2003, 305(1):129-135. 10.1016/S0006-291X(03)00714-9, 12732206.
42. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003, 18(1):41-51. 10.1016/S1074-7613(02)00505-8, 12530974.
43. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 2009, 83(23):12345-12354. 10.1128/JVI.01175-09, 2786768, 19793804.
44. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003, 197(11):1427-1439. 10.1084/jem.20022059, 2193902, 12782710.
45. Schepis D, D'Amato M, Studahl M, Bergström T, Kärre K, Berg L. Herpes simplex virus infection downmodulates nkg2d ligand expression. Scand J Immunol 2009, 69(5):429-436. 10.1111/j.1365-3083.2009.02241.x, 19508374.
46. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 2002, 179(2):205-212. 10.1016/S0304-3835(01)00871-0, 11888675.
47. Antonsson A, Payne E, Hengst K, McMillan NA. The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res 2006, 26(7):455-461. 10.1089/jir.2006.26.455, 16800784.
48. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000, 275(10):6764-6769. 10.1074/jbc.275.10.6764, 10702232.
49. Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol 2010, 84(22):11614-11623. 10.1128/JVI.01053-10, 2977886, 20810727.